ACHV
Achieve Life Sciences, Inc.NASDAQHealthcare$3.23+2.87%ClosedMarket Cap: $172.0M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
8.00
P/S
0.00
EV/EBITDA
-3.08
DCF Value
$0.12
FCF Yield
-28.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-204.1%
ROA
-130.8%
ROIC
-150.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-14.7M | $-0.28 |
| FY 2025 | $0.00 | $-54.6M | $-1.25 |
| Q3 2025 | $0.00 | $-14.4M | $-0.28 |
| Q2 2025 | $0.00 | $-12.7M | $-0.37 |
Analyst Ratings
View AllHC Wainwright & Co.Buy
2026-03-25Trading Activity
Insider Trades
View AllRubinstein Mark Lawrenceofficer: Chief Medical Officer
SellFri Jan 30
Oki Mark Kofficer: Chief Financial Officer
SellFri Jan 30
Xinos Jaimeofficer: Chief Commercial Officer
SellFri Jan 30
Donnelly Craigofficer: Chief Operations Officer
SellFri Jan 30
Stewart Richard Alistairdirector, officer: Chief Executive Officer
SellFri Jan 30
Company Info
Sector
Healthcare
Industry
—
Country
CA
Exchange
NASDAQ
Beta
1.96
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.